Alliancebernstein L.P. Protalix Bio Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 11,720 shares of PLX stock, worth $27,424. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,720Holding current value
$27,424% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
69Shares Held
8.69MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.78 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.53 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$1.93 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$1.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$1.13 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $116M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...